Cargando…
Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms
Monoclonal antibodies (mAbs) for therapeutic applications should be as similar to native human antibodies as possible to minimize their immunogenicity in patients. Several transgenic animal platforms are available for the generation of fully human mAbs. Attributes such as specificity, efficacy and C...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365404/ https://www.ncbi.nlm.nih.gov/pubmed/32673351 http://dx.doi.org/10.1371/journal.pone.0235815 |
_version_ | 1783560026743373824 |
---|---|
author | Cameron, Beatrice Dabdoubi, Tarik Berthou-Soulié, Laurence Gagnaire, Marie Arnould, Isabelle Severac, Anne Soubrier, Fabienne Morales, Jacqueline Leighton, Philip A. Harriman, William Ching, Kathryn Abdiche, Yasmina Radošević, Katarina Bouquin, Thomas |
author_facet | Cameron, Beatrice Dabdoubi, Tarik Berthou-Soulié, Laurence Gagnaire, Marie Arnould, Isabelle Severac, Anne Soubrier, Fabienne Morales, Jacqueline Leighton, Philip A. Harriman, William Ching, Kathryn Abdiche, Yasmina Radošević, Katarina Bouquin, Thomas |
author_sort | Cameron, Beatrice |
collection | PubMed |
description | Monoclonal antibodies (mAbs) for therapeutic applications should be as similar to native human antibodies as possible to minimize their immunogenicity in patients. Several transgenic animal platforms are available for the generation of fully human mAbs. Attributes such as specificity, efficacy and Chemistry, Manufacturing and Controls (CMC) developability of antibodies against a specific target are typically established for antibodies obtained from one platform only. In this study, monoclonal antibodies (mAbs) cross-reactive against human and cynomolgus LAMP1 were derived from the human immunoglobulin transgenic TRIANNI mouse and OmniChicken(®) platforms and assessed for their specificity, sequence diversity, ability to bind to and internalize into tumor cells, expected immunogenicity and CMC developability. Our results show that the two platforms were complementary at providing a large diversity of mAbs with respect to epitope coverage and antibody sequence diversity. Furthermore, most antibodies originating from either platform exhibited good manufacturability characteristics. |
format | Online Article Text |
id | pubmed-7365404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-73654042020-07-27 Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms Cameron, Beatrice Dabdoubi, Tarik Berthou-Soulié, Laurence Gagnaire, Marie Arnould, Isabelle Severac, Anne Soubrier, Fabienne Morales, Jacqueline Leighton, Philip A. Harriman, William Ching, Kathryn Abdiche, Yasmina Radošević, Katarina Bouquin, Thomas PLoS One Research Article Monoclonal antibodies (mAbs) for therapeutic applications should be as similar to native human antibodies as possible to minimize their immunogenicity in patients. Several transgenic animal platforms are available for the generation of fully human mAbs. Attributes such as specificity, efficacy and Chemistry, Manufacturing and Controls (CMC) developability of antibodies against a specific target are typically established for antibodies obtained from one platform only. In this study, monoclonal antibodies (mAbs) cross-reactive against human and cynomolgus LAMP1 were derived from the human immunoglobulin transgenic TRIANNI mouse and OmniChicken(®) platforms and assessed for their specificity, sequence diversity, ability to bind to and internalize into tumor cells, expected immunogenicity and CMC developability. Our results show that the two platforms were complementary at providing a large diversity of mAbs with respect to epitope coverage and antibody sequence diversity. Furthermore, most antibodies originating from either platform exhibited good manufacturability characteristics. Public Library of Science 2020-07-16 /pmc/articles/PMC7365404/ /pubmed/32673351 http://dx.doi.org/10.1371/journal.pone.0235815 Text en © 2020 Cameron et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Cameron, Beatrice Dabdoubi, Tarik Berthou-Soulié, Laurence Gagnaire, Marie Arnould, Isabelle Severac, Anne Soubrier, Fabienne Morales, Jacqueline Leighton, Philip A. Harriman, William Ching, Kathryn Abdiche, Yasmina Radošević, Katarina Bouquin, Thomas Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms |
title | Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms |
title_full | Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms |
title_fullStr | Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms |
title_full_unstemmed | Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms |
title_short | Complementary epitopes and favorable developability of monoclonal anti-LAMP1 antibodies generated using two transgenic animal platforms |
title_sort | complementary epitopes and favorable developability of monoclonal anti-lamp1 antibodies generated using two transgenic animal platforms |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365404/ https://www.ncbi.nlm.nih.gov/pubmed/32673351 http://dx.doi.org/10.1371/journal.pone.0235815 |
work_keys_str_mv | AT cameronbeatrice complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT dabdoubitarik complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT berthousoulielaurence complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT gagnairemarie complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT arnouldisabelle complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT severacanne complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT soubrierfabienne complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT moralesjacqueline complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT leightonphilipa complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT harrimanwilliam complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT chingkathryn complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT abdicheyasmina complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT radosevickatarina complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms AT bouquinthomas complementaryepitopesandfavorabledevelopabilityofmonoclonalantilamp1antibodiesgeneratedusingtwotransgenicanimalplatforms |